Viz.ai is the leader in applied artificial intelligence in healthcare. It was inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late.
Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care.
Viz.ai was founded in Israel in 2016 by Chris Mansi, David Golan and Manoj Ramachandran. The company is headquartered in San Francisco, California, with offices in Tel Aviv, Portugal and Amsterdam.
Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,000 hospitals in the US and EMEA.
Viz.ai’s life science portfolio expands the power of the AI-powered Viz Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently
Viz is backed by Tiger Global, Insight Partners, Kleiner Perkins, Greenoaks, GV, Scale Venture Partners, Threshold, Innovation Endeavors, Sozo Ventures, CRV, Susa, and others. The company raised $100M in Series D round on Apr 07, 2022. This brings Viz's total funding to $251.6M to date. The latest round mints Viz.ai a unicorn with a valuation of $1.2B post-money.